Litcius/Paper detail

Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery

Stuart A. Grossman, Carlos G. Romo, Michelle A. Rudek, Jeffrey G. Supko, Joy Fisher, Burt Nabors, Patrick Y. Wen, David M. Peereboom, Benjamin M. Ellingson, William F. Elmquist, Fred G. Barker, David Kamson, Jann N. Sarkaria, William C. Timmer, Ranjit S. Bindra, Xiaobu Ye

2020Neuro-Oncology37 citationsDOIOpen Access PDF

Abstract

Author(s): Grossman, Stuart A; Romo, Carlos G; Rudek, Michelle A; Supko, Jeffrey; Fisher, Joy; Nabors, L Burt; Wen, Patrick Y; Peereboom, David M; Ellingson, Benjamin M; Elmquist, William; Barker, Fred G; Kamson, David; Sarkaria, Jann N; Timmer, William; Bindra, Ranjit S; Ye, Xiaobu

Topics & Concepts

GrossmanBrain cancerPsychoanalysisPsychologyMedicineCancerInternal medicineKeynesian economicsEconomicsGlioma Diagnosis and TreatmentRadiomics and Machine Learning in Medical ImagingBrain Metastases and Treatment
Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery | Litcius